Analysis of cytokines in tear fluid from atopic dermatitis patients with dupilumab-associated ocular adverse events.
Fiche publication
Date publication
octobre 2021
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
Tous les auteurs :
Vuillemey L, Febvay C, Puzenat E, Bellanger AP, Chague C, Puyraveau M, Delbosc B, Gauthier AS, Aubin F
Lien Pubmed
Résumé
Although the introduction of dupilumab has revolutionized the management of atopic dermatitis (AD), dupilumab-associated ocular adverse events (DAOAE) represent the first cause for discontinuation of dupilumab. The exact pathogenesis of DAOAE events observed is unknown. We conducted a prospective study from October 2019 to June 2020 to determine the feasibility of cytokine analysis in tear fluid obtained by non-invasive capillarity from AD patients treated with dupilumab and to compare the inflammatory cytokine profiles before and during dupilumab treatment between patients with and without DAOAE.
Mots clés
atopic dermatitis, cytokines, dupilumab, ocular adverse event, tear fluid
Référence
J Eur Acad Dermatol Venereol. 2021 Oct 8;: